Theriva Biologics Q3 EPS $(0.19) Beats $(0.38) Estimate; $31.2M In Cash, Which Is Expected To Provide Runway Into The First Quarter Of 2025
Portfolio Pulse from Benzinga Newsdesk
Theriva Biologics (AMEX:TOVX) reported Q3 EPS of $(0.19), surpassing the $(0.38) estimate and marking a 36.67% improvement from last year's $(0.30) per share loss. The company has $31.2M in cash, expected to last until Q1 2025.
November 13, 2023 | 1:05 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Theriva Biologics reported better-than-expected Q3 earnings and has sufficient cash to last until Q1 2025, indicating a strong financial position in the short term.
Beating EPS estimates typically generates positive investor sentiment, which can lead to a short-term increase in stock price. The company's reported improvement over last year's losses and a solid cash runway also contribute to a positive outlook.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100